What are Ionis Pharmaceuticals's profit margins?

Ionis Pharmaceuticals (IONS) runs a 98.4% gross margin and a -33.3% operating margin, with a -30.9% net margin.

Where do Ionis Pharmaceuticals's ratios come from?

Every ratio is computed from Ionis Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

Ionis Pharmaceuticals IONS Ratios & Valuation

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Profitability
Gross margin	98.3%-0.1pp	98.4%-0.4pp	98.8%+1.2pp	97.6%-1.1pp
Operating margin	-40.4%+26.9pp	-67.4%-22.5pp	-44.9%+24.9pp	-69.8%-66.1pp
Net margin	-40.4%+24.0pp	-64.4%-17.9pp	-46.5%-0.6pp	-45.9%-42.4pp
Returns
Return on equity	-70.8%+22.3pp	-93.1%-16.8pp	-76.3%-36.2pp	-40.1%-36.3pp
Return on invested capital	-24.2%+91.4pp	-115.6%-21.4pp	-94.2%—	——
Efficiency
Asset turnover	0.3×+0.1×	0.2×0.0×	0.3×+0.1×	0.2×-0.1×
Liquidity
Current ratio	3.8×-4.6×	8.5×+2.6×	5.9×-1.2×	7.1×-2.7×
Leverage
Debt-to-equity	5×+4.7×	0.4×-0.3×	0.7×+0.3×	0.4×+0.2×
Per Share
Book value per share	$3.06-22.3%	$3.94+45.7%	$2.70-33.1%	$4.04-16.1%
Valuation
Market capitalization	$12.81B+132%	$5.52B-24.2%	$7.28B+35.8%	$5.36B+24.5%
Price / sales	13.6×+5.7×	7.8×-1.4×	9.2×+0.1×	9.1×+3.8×
Price / book	26.2×+16.8×	9.4×-9.5×	18.8×+9.5×	9.4×+3.8×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Ionis Pharmaceuticals.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Ionis Pharmaceuticals's profit margins?: Ionis Pharmaceuticals (IONS) runs a 98.4% gross margin and a -33.3% operating margin, with a -30.9% net margin.
Where do Ionis Pharmaceuticals's ratios come from?: Every ratio is computed from Ionis Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.